<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70507">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909141</url>
  </required_header>
  <id_info>
    <org_study_id>fem2013</org_study_id>
    <nct_id>NCT01909141</nct_id>
  </id_info>
  <brief_title>Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS</brief_title>
  <official_title>Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <authority>Egypt: Cairo University-Faculty of Medicine</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age.
      Hyperinsulinemia contributes to chronic anovulation commonly encountered in women with PCOS.
      The first choice therapy is clomiphene citrate (CC). In CC resistant cases, the American
      College of Obstetrics and Gynecology (ACOG) recommends the use of insulin sensitizer
      metformin. Other insulin sensitizing agents include rosiglitazone and pioglitazone.
      Pioglitazone is said to improve fertility and ovulation in patients with PCOS.CC may be
      associated with poor endometrial thickening due to its antiestrogenic effect. Letrozole may
      improve this condition. In this study we will compare the effect of combined
      letrozole-metformin-pioglitazone with that of combined CC-metformin-pioglitazone in
      ovulation induction in CC-resistant PCOS women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age.
      Hyperinsulinemia contributes to chronic anovulation commonly encountered in women with PCOS.
      The first choice therapy is clomiphene citrate (CC). In CC resistant cases, the ACOG
      recommends the use of insulin sensitizer metformin. Other insulin sensitizing agents include
      rosiglitazone and pioglitazone. Pioglitazone is said to improve fertility and ovulation in
      patients with PCOS.CC has a long half-life (2 weeks), and this may have a negative effect on
      the cervical mucus and endometrium, leading to discrepancy between ovulation and conception
      rates. There has been a search for a compound capable of inducing ovulation but devoid of
      the adverse antiestrogenic effects of CC. recent studies have suggested that letrozole, an
      aromatase inhibitor, does not possess the adverse antiestrogenic effects of CC and is
      associated with higher pregnancy rates than CC treatment in patients with PCOS.

      In this study we shall compare the effect of combined letrozole-metformin-pioglitazone with
      that of combined CC-metformin-pioglitazone in ovulation induction in CC-resistant PCOS
      women.This will be a prospective comparative clinical trial in which 2 groups of women will
      be generated (groups A and B) using the sealed envelopes randomization method.Group A (40
      women) will receive: letrozole 2.5 mg/day from 3rd day of the cycle for 5 days and
      (pioglitazone 15 mg + metformin 850 mg) once daily from 1st day of the cycle for 10 days.
      Group B (40 women) will receive  clomiphene citrate 100 mg/day from 3rd day of the cycle for
      5 days and (pioglitazone 15 mg + metformin 850 mg) once daily from 1st day of the cycle for
      10 days. Ovulation will be monitored by vaginal ultrasound and serum estrogen and
      progesterone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ovulation rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of follicles&gt;18mm.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>safety of pioglitazone as regards kidney functions.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>kidney functions (blood urea and serum creatinine) will be assayed pretreatment and repeated every month during the treatment period (3 cycles) to find out any hazards of pioglitazone on kidney functions.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction of ovulation using letrozole-pioglitazone-metformin</intervention_name>
    <description>induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction of ovulation using clomiphene citrate-pioglitazone-metformin</intervention_name>
    <description>induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.</description>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>transvaginal ultrasound</intervention_name>
    <description>transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of &gt; 18 mm or till day 20 of the cycle</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>body mass index (BMI) calculation</intervention_name>
    <description>BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone</intervention_name>
    <description>baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pretreatment blood urea and serum creatinine</intervention_name>
    <description>blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum estradiol (E2) on day 12</intervention_name>
    <description>serum E2 will be assayed on day 12 of the cycle for all women.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum progesterone on day 21</intervention_name>
    <description>serum progesterone will be assayed on day 21 for all women to monitor ovulation.</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood urea and serum creatinine every month</intervention_name>
    <description>blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions</description>
    <arm_group_label>arm 1:letrozole-pioglitazone -metformin group</arm_group_label>
    <arm_group_label>arm 2: clomiphene citrate-pioglitazone-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-40 years old

          -  PCOS infertile women resistant to CC for3 cycles

        Exclusion Criteria:

          -  presence of medical disorders as diabetes, hypertension, cardiac problems, liver or
             kidney diseases, hyperprolactinemia or thyroid dysfunction.

          -  use of gonadotropins before

          -  previous ovarian drilling

          -  presence of urinary symptoms especially bloody urine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ghada Abdel Fattah Abdel Moety, lecturer</last_name>
    <phone>00201006513305</phone>
    <email>ghadaabdelfatah2007@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ghada Abdel Fattah Abdel Moety, lecturer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 24, 2013</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ghada Abdel Fattah</investigator_full_name>
    <investigator_title>lecturer of Obstetrics and Gynecology-Cairo University</investigator_title>
  </responsible_party>
  <keyword>letrozole</keyword>
  <keyword>clomiphene citrate</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>metformin</keyword>
  <keyword>ovulation induction</keyword>
  <keyword>PCOS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
